Welcome to our dedicated page for Evaxion AS SEC filings (Ticker: EVAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Evaxion A/S filings document a foreign private issuer that furnishes Form 6-K reports for business updates, financial results, clinical and preclinical vaccine-program disclosures, and governance actions. Recent reports describe AI-Immunology™-powered vaccine development, EVX-01 personalized cancer vaccine data in advanced melanoma, platform work in glioblastoma, and infectious disease vaccine design concepts.
The filing record also includes annual general meeting results, approval of the audited annual report, board and auditor elections, leadership-role disclosures, and incorporation of Form 6-K reports by reference into Form S-8, Form F-1, and Form F-3 registration statements. These documents frame Evaxion’s capital-market disclosures around pipeline development, corporate governance, securities registrations, and recurring operating updates.
Evaxion A/S is highlighting progress on its EVX-04 cancer vaccine program by presenting new preclinical data at the EHA 2026 Congress. The poster on June 13, 2026 will cover the functional characterization of EVX-04, an off-the-shelf therapeutic vaccine candidate for acute myeloid leukemia.
Developed using Evaxion’s AI-Immunology™ platform, EVX-04 targets endogenous retrovirus tumor antigens that are present in AML tumors but not in normal tissue. In preclinical models, all 16 antigen fragments in EVX-04 trigger specific immune responses and prevent tumor growth, supporting its potential as a broadly applicable off-the-shelf vaccine.
The company states that these data are another step toward clinical testing and that it plans to submit a clinical trial application for EVX-04 in the second half of 2026. Background in the report underscores the high unmet need in AML, where survival rates remain low despite intensive and low-intensity chemotherapy options.
Evaxion A/S reported first quarter 2026 results alongside a broad business update. The company remains focused on its AI-Immunology™ platform, which showed 86% vaccine target recognition in its personalized cancer vaccine EVX-01, reinforcing the platform’s ability to trigger tumor-specific immune responses.
Evaxion completed a one-year extension of its phase 2 EVX-01 melanoma trial and plans to present three-year data in the second half of 2026. It also presented new polio vaccine design concepts from its collaboration with The Gates Foundation and data supporting AI-Immunology™ use in glioblastoma.
For the quarter, Evaxion recorded a net loss of $3.6 million, compared with $1.6 million a year earlier, mainly due to lower finance income. Cash and cash equivalents were $18.4 million as of March 31, 2026, supporting a cash runway into the second half of 2027.
Evaxion A/S, a clinical-stage TechBio company using its AI-Immunology™ platform to develop novel vaccines for cancer and infectious diseases, has scheduled a business update and its first quarter 2026 financial results release for May 7, 2026 before the opening of the Nasdaq CM.
The company’s executive management will host a conference call and webcast on the same day at 14:30 CET / 08:30 EST to present the update and results and take questions. Registration is required to receive dial-in details and a unique PIN, and a webcast recording will be available on Evaxion’s website afterward.
Evaxion A/S, a clinical-stage TechBio company developing AI-Immunology™ powered vaccines, has promoted Chief Scientific Officer Birgitte Rønø to a dual role as Chief Scientific and Chief Operating Officer. This change follows an internal management review aimed at aligning the organization to better execute its strategy and increase external visibility of its AI-Immunology™ platform with partners and investors.
The promotion recognizes Dr. Rønø’s long-standing contribution to Evaxion’s internal operations and scientific leadership. Following the change, the management team consists of CEO Helen Tayton-Martin, CSO and COO Birgitte Rønø, CFO Thomas Schmidt, and Chief AI Officer Andreas Mattsson. The filing also reiterates Evaxion’s focus on AI-driven vaccine candidates for cancer and infectious diseases.
Evaxion A/S director Jens Bitsch-Norhave filed an initial Form 3 reporting indirect ownership of 2,376 Ordinary Shares. The shares are held through Sprout Invest Aps, an entity owned 50% by Mr. Bitsch-Norhave and 50% by his spouse. The filing does not report any new buy or sell transactions.
Evaxion A/S reported the results of its Annual General Meeting held on April 16, 2026. Shareholders representing 104,894,401 ordinary shares, or 25,15 % of the share capital, were present or represented.
The audited annual report for 2025 and the carry-forward of the 2025 loss were approved. All incumbent directors standing for election were re-elected, and Jens Bitsch-Nørhave joined as a new board member. EY Godkendt Revisionspartnerselskab was re-appointed as auditor.
Shareholders approved an increase in the board’s authorization to issue warrants up to a nominal DKK 11,900,000, valid until April 15, 2029, and a new authorization to obtain loans through convertible loan notes up to a nominal DKK 73,500,000, valid until April 15, 2031, both without pre-emptive rights for existing shareholders. The Articles of Association were amended accordingly.
Evaxion A/S reports new phase 2 data for its personalized cancer vaccine EVX-01, showing that 86% of vaccine targets selected by its AI-Immunology™ platform triggered a tumor-specific immune response in advanced melanoma patients. The company also observed durable vaccine-specific immune responses lasting at least two years and a high rate of de novo tumor-specific T cells, indicating strong immune activation. The ongoing phase 2 trial combines EVX-01 with MSD’s KEYTRUDA® and has previously delivered a 75% Objective Response Rate, with three-year clinical data planned for the second half of 2026. The new data will be presented at the AACR Annual Meeting on April 22, 2026.
Evaxion A/S reports new phase 2 data for its personalized cancer vaccine EVX-01, showing that 86% of vaccine targets selected by its AI-Immunology™ platform triggered a tumor-specific immune response in advanced melanoma patients. The company also observed durable vaccine-specific immune responses lasting at least two years and a high rate of de novo tumor-specific T cells, indicating strong immune activation. The ongoing phase 2 trial combines EVX-01 with MSD’s KEYTRUDA® and has previously delivered a 75% Objective Response Rate, with three-year clinical data planned for the second half of 2026. The new data will be presented at the AACR Annual Meeting on April 22, 2026.
Evaxion A/S, a clinical-stage TechBio company, reports new data from its AI-Immunology™ platform showing it can design personalized cancer vaccines for glioblastoma, a deadly brain cancer with limited treatment options.
Working with Duke University School of Medicine, Evaxion identified endogenous retrovirus (ERV)-derived antigens and additional neoantigens in glioblastoma tumor samples. ERVs, which are present in tumors but absent in normal tissue, are highlighted as an attractive new antigen source. Bioinformatic and experimental data indicate ERV-derived antigens can trigger immune responses and may help overcome challenges linked to low mutational burden in glioblastoma. The data will be presented at the American Association for Cancer Research Annual Meeting in San Diego on April 22, 2026.
Evaxion A/S, a clinical-stage TechBio company, reports new data from its AI-Immunology™ platform showing it can design personalized cancer vaccines for glioblastoma, a deadly brain cancer with limited treatment options.
Working with Duke University School of Medicine, Evaxion identified endogenous retrovirus (ERV)-derived antigens and additional neoantigens in glioblastoma tumor samples. ERVs, which are present in tumors but absent in normal tissue, are highlighted as an attractive new antigen source. Bioinformatic and experimental data indicate ERV-derived antigens can trigger immune responses and may help overcome challenges linked to low mutational burden in glioblastoma. The data will be presented at the American Association for Cancer Research Annual Meeting in San Diego on April 22, 2026.
Evaxion A/S, a clinical-stage TechBio company developing AI-Immunology™-powered vaccines, reported the results of its Annual General Meeting held at its offices in Denmark. The 2025 Annual Report was approved and all proposals from the Board of Directors were passed.
Shareholders re-elected Marianne Søgaard, Lars Holtug, Lars Aage Staal Wegner and Roberto Prego Pineda to the Board of Directors, and elected Jens Bitsch Nørhave as a new Board member. The company noted that minutes from the meeting are available on its website and reiterated its focus on AI-driven vaccine candidates in oncology and infectious diseases.
Evaxion A/S CAIO Andreas Holm Mattsson filed an amended Form 3 to detail his ownership of ordinary shares and warrants. He holds 1,382,395 ordinary shares directly and 4,142,521 ordinary shares indirectly through Mattsson Holding af 2008 ApS, where he is described as a control person.
The filing also lists several series of warrants over ordinary shares. These include warrants over 55,147 shares with a 0.7400 exercise price expiring on December 21, 2026, and warrants over 645,700 shares at 0.0590 per share expiring on January 31, 2030. Additional warrant positions cover 35,000 shares at 2.2300, 6,250 shares at 0.7500, 25,000 shares at 0.4000, and 125,000 shares at 0.0700, each expiring on December 31, 2031. Footnotes explain that some warrants arise from a private placement that closed on December 21, 2023 and a public offering that closed on January 31, 2025, with certain awards vesting monthly over 36 months from their initial exercise dates.